India Biotech Disappointed: Not Enough Tax Incentives

The financial budget of India for the year 2006Recently, several state governments such as in
has caused reasons to disappoint its biotechMaharashtra, Andhra Pradesh and Karnataka have
sector. The first shortfall was in dowsingtaken proactive initiatives to promote
expectations on the tax structure. While currentlybiotechnology by implementing different
only costs of Indian patent filings are included inbiotechnology policies. These policies focus on
weighted tax deductions, the biotech sector nowsetting up Biotech Parks, Incubators, Centers of
wants costs of international patent filings also toBiotech Excellence and providing fiscal incentives
be included.to investors.
The second shortfall pertains to restraining taxesA market research report named "Indian
on technology transfers and technology licensingBiotechnology Market Outlook (2006)"
on which the biotech industry relies heavily toprepared by RNCOS gives a detailed analysis of
launch new technologies. This dependence is morethe Indian biotech market structure and conditions.
as world biotech companies usher advancedIt also delineates the initiatives and policies of
medicinal and agricultural techniques into thecentral and state governments.
country. So the biotech industry wantsPrior to this, the report assesses the Indian
exemptions on withholding taxes on these.biotechnology market for 2005 in terms of size,
Entrepreneurs argue that the biotech sectordemand, domestic market and exports. It also
needs this kind of support to compete withforecasts for the same till 2010. An intensive
countries like China, Singapore, Korea and EasternSWOT analysis is also covered in the report. The
Europe. The industry therefore hopes that itsanalysts discuss about the future of biotechnology
demand would be met by the new nationalin India as also how the government initiatives and
biotech policy that is to be announced later thisresulting regulations are affecting the industry.
year.Finally the report lists company profiles of 20
The financial budget has also disappointed themajor players in biotech industry including Shantha
industry by not relaxing export obligations forBiotechnics, Biocon, Bharat Biotech, Wockhardt,
newly formed biotech companies in the biotechSerum Institute of India, Zydus Cadila, and
"parks" coming up in all economicAventis Pharma.
zones of the country.